Citigroup
BRTX icon

Citigroup’s BioRestorative Therapies BRTX Stock Holding History

Citigroup’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Buy
+63,724
New +$18.6K ﹤0.01% 5128
2025
Q4 		– Sell
-1
Closed -$1 – 6092
2025
Q3 		$1 Buy
+1
New +$2 ﹤0.01% 6035

Other funds holding BRTX

VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup's BRTX Position: Q2 2026 in Review

Citigroup opened a new position in BioRestorative Therapies (BRTX) in Q2 2026: 63,724 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #5128 among its holdings. This is a return to the name: Citigroup previously reported a position in BRTX as recently as Q3 2025.

Citigroup first reported a position in BRTX in Q3 2025 and has held it in 2 quarters since. 15 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.

  • Citigroup held 63,724 shares of BioRestorative Therapies worth $24K as of Q2 2026.
  • BioRestorative Therapies was a new Citigroup position in Q2 2026.
  • BioRestorative Therapies made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5128 holding.
  • Citigroup first reported a position in BioRestorative Therapies in Q3 2025 and has held it in 2 quarters since.
  • 15 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.